GSK and Alamar will profile more than 60,000 ser

From brain scans to Super Mario, NeuroAge and Tr

Sironax announced that two abstracts on its NAMPT

NorthStrive Biosciences completed an eight-week p

Built with David Sinclair for Grok Bot, the free

BioCardia has completed the clinical consultation

MetaVia released interim Part 3B results from its

Elysium Health announced plans to offer six addit

Insilico Medicine announced the open-source relea

Eisai’s CTAD slate includes five-year Clarity

A gene therapy heading toward its first human tr

Analysis of 41,000 companion dogs finds they sha

SIR2501, a SARM1 blocker with FDA Fast Track sta

Employers get one platform for GLP-1 access, hor

A new review argues that aging has several brake

Resolution Therapeutics announced positive interi

Circular Genomics, Inc. and PharmatrophiX, Inc.

A Frontiers in Aging perspective pitches encapsu

RoC is recruiting at least 30 pairs of women 40

The Swiss drugmaker ends a blood-brain barrier p

Designerly’s Cooper Adwin on why regulatory go

Viome acquired Sōlaria Biō.

The acquisition marks Viome’s latest step in ex

Humanaut Health announced six new franchise and c

Daiichi Sankyo and AstraZeneca have entered into

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/S

A randomized, double-blind, placebo-controlled tr

Ultrahuman’s racing partnership is about more

Alamar and Nightingale will hunt rare, low-level

A late-breaking slot in Boston will bring fresh

Tiny Health announced two new features, Microbiom

Revive Health and FitOn Health have combined to f

Six-month University of Surrey RCT sees better e

L-Nutra Health launches a clinician-led metaboli

A Phase 1 study of MNA-001, which targets TREM2,

Emory researchers say a 10-protein plasma signat

Eliquent Life Sciences has joined ExoCordOA, a €13 million, five-year Horizon Europe consortium coordinated by Exogenus Therapeutics that aims to advance extracellular vesicle-enriched secretome therapies toward clinical use, initially targeting osteoarthritis. The program intends to support Phase I and II development of Exogenus’s lead candidate, EXO-101, as a potential disease-modifying treatment, while addressing scientific, manufacturing, quality-control, and regulatory challenges that affect the translation of secretome-based medicines. Eliquent will provide regulatory development expertise to the ten-organization consortium, which includes biotechnology, manufacturing, clinical and academic partners such as Lonza, Anthony Nolan, Utrecht University and Maastricht University Medical Center+. The consortium also plans to develop more standardized approaches, robust analytical and potency-assessment methods and a clearer regulatory pathway for future secretome therapies. According to the consortium announcement, osteoarthritis affects about 8% of the global population, and no disease-modifying osteoarthritis drugs are currently approved. The company claims its integrated expertise spans regulatory affairs, quality and compliance, and pharmacovigilance and safety. The post Eliquent joins €13m Horizon Europe consortium appeared first on Longevity.Technology.

Superpower has launched Superpower Peptides, offe

Fractyl’s Revita hit its six-month goal in a s

Latus Bio‘s Nature Communications paper models

Twelve abstracts head to The Liver Meeting, incl

Why the next breakthroughs in healthy aging may

LifeVantage released results of a two-part in vit

Exogenus Therapeutics is coordinating ExoCordOA,

Fractyl has expanded its U.S.

John Hancock and MIT AgeLab’s second index fin

The preclinical results for RV-8451, an oral GLP

NeuroXT’s NEXT-Cue pairs brain MRI with cognit

Prenuvo and UT Dallas researchers found links be

Five-year research program will examine how gene